Skip to main content
padlock icon - secure page this page is secure

Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva

Buy Article:

$52.00 + tax (Refund Policy)

Nückel H, Meller D, Steuhl K-P, Dührsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.

Eur J Haematol 2004: 73: 258–262. © Blackwell Munksgaard 2004. Abstract: 

Low-grade non-Hodgkin's lymphomas of the conjunctiva may be cured by radiotherapy, but complications are frequent and relapses may occur. Other treatment modalities including resection, cryotherapy, injection of interferon-α or systemic chemotherapy have been used with varying success. We treated two patients with relapsed extranodal marginal zone lymphoma (ENMZL) of mucosa-associated lymphoid tissue (MALT) of the conjunctiva with the anti-CD20 monoclonal antibody rituximab (375 mg/m2 intravenously once weekly for 4 wk) which has previously been shown to be effective in a variety of other B-cell non-Hodgkin's lymphomas. Treatment was well tolerated and resulted in one partial and one complete remission. With a follow-up of 32 or 30 months, respectively, further recurrences have not been observed. Rituximab is a highly effective and well-tolerated treatment of conjunctival MALT lymphoma, which may not only be of value in relapse, but also in cases of contraindication to radiotherapy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: anti-CD20 monoclonal antibody; conjunctiva; extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type; rituximab

Document Type: Research Article

Affiliations: 1: Department of Hematology 2: Department of Ophthalmology, Medical Faculty, University of Essen, Germany

Publication date: October 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more